EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
Details
- Status
- Prescription
- First Approved
- 2025-02-28
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Approval History
What EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Treats
1 FDA approvalsOriginally approved for its first indication in 2025 .
- Other (1)
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE FDA Label Details
ProIndications & Usage
FDA Label (PDF)Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.